Korean J Hematol.  2012 Jun;47(2):146-149. 10.5045/kjh.2012.47.2.146.

Cyclosporine A treatment for relapsed subcutaneous panniculitis-like T-cell lymphoma: a case with long-term follow-up

Affiliations
  • 1Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. lwshmo@gshp.gsnu.ac.kr
  • 2Department of Pathology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea.
  • 3Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan, Korea.

Abstract

Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a distinctive lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic cytotoxic T cells. There was no distinction between TCR alpha/beta phenotype and TCR gamma/delta phenotype, and anthracycline-based chemotherapy was usually used for both. Here, we report a patient with recurrent SPTL who achieved a second long-term complete remission by repeated cyclosporine A (CsA) treatment. From 2000 to 2001, the patient received anthracycline-based combination chemotherapy. However, the treatment did not induce long-term remission. In 2002, he received cyclosporine treatment for about 6 months. This resulted in a 5-year remission that ended in relapse in 2008. He received CsA treatment once again and attained a second long-term remission. This case suggests that re-treatment with CsA can be a good option for relapsed SPTL cases and can result in long-term remission.

Keyword

Subcutaneous panniculitis-like T-cell lymphoma; Cyclosporine; Treatment outcome

MeSH Terms

Cyclosporine
Drug Therapy, Combination
Follow-Up Studies
Humans
Lymphoma
Lymphoma, T-Cell
Panniculitis
Phenotype
Recurrence
Subcutaneous Tissue
T-Lymphocytes
Treatment Outcome
Cyclosporine
Lymphoma, T-Cell
Panniculitis
Full Text Links
  • KJH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error